SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Regenicin, Inc (RGIN)

RGIN RSS Feed
Add RGIN Price Alert      Hide Sticky   Hide Intro
Moderator: HDOGTX
Search This Board:
Last Post: 9/15/2016 10:30:32 AM - Followers: 81 - Board type: Free - Posts Today: 0

Regenicin, Inc.
10 High Court
Little Falls, NJ 07424

**updated and correct phone number**  (973) 557-8914

 they filed this on aug 22 2016-  http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11558959  
 

   
Name: Randall McCoy
Title: Principal Executive Officer and Director
Date: August 22, 2016

 

   
Name: John J. Weber
Title: Principal Financial Officer and Director
Date: August 22, 2016


home.jpg

FDA Issues Status Approval for PermaDerm®    sold to AMBS for 3,500,000$ in cash + 3,000,000$ in AMBS stocks

LITTLE FALLS, N.J., June 12, 2012 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that the Food and Drug Administration (FDA) has granted Orphan Status approval for the PermaDerm® product, the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers, that is indicated for catastrophic burn patients.  The FDA had previously designated PermaDerm® to be a biological/drug (permanent skin replacement) not a medical device (temporary skin replacement). PermaDerm® is the only skin replacement technology to receive this Biological/drug designation.

COMPANY HIGHLIGHTS:

  • PermaDerm® is the only skin replacement technology to receive this Biological/drug designation
    Only 83million shares outstanding A/O May 18th, 2012
    Recently release their 10Q CLICK HERE TO VIEW
    PermaDerm technology has been clinically tested in over 150 pediatric, catastrophic burn patients. Currently Regenicin is working with its contract manufacturer to prepare for pre-market approval of PermaDerm™ from the FDA.
    Cambrex Biosciences, the company that owned Cutanogen, which holds the license rights to PermaDermTM, to help in the regulatory process to gain FDA approval of PermaDermTM. When Lonza purchased Cambrex they also purchased Cutanogen. Lonza's core business is contract manufacturing of cell therapy bio medical products. They did not wish to pursue FDA approval or market the product. Mr. McCoy, understanding the value of the product and familiar with the regulatory process, offered to purchase the rights to the product. So we believe that Lonza entered into the Know-How and License Agreement (the "Agreement") because we have expertise in working with the FDA on the approval




 

home

 

About PermaDerm

PermaDerm™ is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.

These living, self-to-self skin graft tissue are intended to form permanent skin tissue that will not be rejected by the immune system of the patient, a critical possibility in porcine or cadaver skin grafts used today.

The technology has been clinically tested in over 150 pediatric, catastrophic burn patients. Currently Regenicin is working with its contract manufacturer to prepare for pre-market approval of PermaDerm™ from the FDA.

PermaDerm™ is being designed to save lives, reduce healthcare costs by decreasing the patient's stay in the Critical Care Unit and reduce the need for additional surgeries. An insurance company procedural code has been approved for reimbursement of costs to hospitals. The American Medical Association has assigned CPT (Current Procedural Terminology) code for cultured skin substitutes under the dermal substitute category which enables insurance companies to process and hospitals to be reimbursed for cultured skin substitutes once approved by the FDA.

home
 

For Burns

burn-1_380

According to the American Burn Association, there are currently over 2,000 cases annually involving burns covering over 50% of the patient's total body surface area.

PermaDerm™ is being developed for the treatment of catastrophic, full-thickness burns covering over 50% of the total body surface area.

PermaDerm™ has been used in clinical trials on pediatric patients with catastrophic burns covering from 50 to 90+% of their body.

PermaDerm™ is being developed to require less donor skin from the patient's own body, thus needing fewer surgeries to harvest skin. The result is expected to be less scarring, with fewer infections and faster healing.

 

Board of Directors

Randall McCoy
Chief Executive Officer
 
Randall McCoy has more than 37 years of experience in the healthcare industry. His experience includes executive positions and scientific research and development. His previous employment includes George Washington University, Temple University Medical School and RCA/SRI International (Director of Life Sciences and Electronic Displays). Mr. McCoy has assisted both small and major pharmaceutical/device companies address FDA issues. He has also helped over 225 foreign and domestic companies introduce their FDA regulated drug and medical device products into the US and World market. Mr. McCoy currently has over 30 Patents US and International.


Changed to AMBS
Dr. Joseph Rubinfeld
Ph.D
Director at CytRX; Initial Co-Founder of Amgen, Inc.
 
Dr. Joseph Rubinfeld co-founded SuperGen, Inc. in 1991 and has served as its Chief Executive Officer and President, Chief Scientific Officer and as a director. He has been a director of CytRX since July 2002. Dr. Rubinfeld is also a founder of JJ Pharma. Dr. Rubinfeld was one of the four initial founders of Amgen, Inc. in 1980 and served as a Vice President and its Chief of Operations until 1983. From 1987 until 1990, Dr. Rubinfeld was a Senior Director at Cetus Corporation and from 1968 to 1980, Dr. Rubinfeld was employed at Bristol-Myers Company. Dr. Rubinfeld received a B.S. degree in chemistry from C.C.N.Y. and an M.A. and Ph.D in chemistry from Columbia University.


John Weber
Regenicin™'s Interim CFO
 
John Weber most recently served as Executive Vice President of Fujifilm USA, the highest ranked American corporate officer, from 2006 until his departure in 2009. His responsibilities included overseeing all corporate activity with the exception of R&D. During that time Fujifilm was ranked as the fastest growing medical imaging company, consistently ranking #1 or #2 in customer satisfaction. From 1998 through 2006 he served as Senior Vice President, Operations at Fujifilm USA where he spearheaded the transition of the company from a film distributor to a digital medical informatics company. From 1986 until 1998 he served as CFO where he helped to profitably manage Fuji's growth from an employee base of 75 to over 1,000. Prior to his distinguished career at Fujifilm USA, Mr. Weber served as the CFO for the confectionary and drinks division of Cadbury Schweppes Limited for three years and as Corporate Controller for an additional five years.


Dr. Craig Eagle
Pfizer Oncology
 
Dr. Craig Eagle joined Pfizer Australia in 2001 as part of the medical group. In Australia, his role involved leading and participating in scientific research, regulatory and pricing & re-imbursement negotiations for compounds in therapeutic areas including oncology, anti-infectives, respiratory, arthritis and pain management. In 2003, Pfizer relocated Dr. Eagle to the United States where he was appointed as the worldwide lead for development of Celecoxib in oncology to oversee the global research program. Since that time he has had increasing responsibility for overseeing the global research plans and teams for Irinotecan and Dalteparin. In 2007, he became head of Medical Affairs and Outcomes Research for Pfizer, including the US oncology business. Dr. Eagle has led, or been directly involved with, teams that resulted in eight new products or indications. As part of his current role at Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses and portfolio.


 

Beneficial Owner                                  Number of shares beneficially owned (1)                 Percentage owned (2)

Officers and Directors

Randall McCoy                                                                                                                   33,727,313(3)                                                                                         

John J. Weber                                                                                                                          935,672(4)

Chris Hadsall

Joseph Rubinfeld                                                                                                                  1,935,672(5)                                                                                                             

Craig Eagle                                                                                                                                935,672(6)

Officers and Directors collectively                                                                                    37,514,329(7)

5 Percent Shareholders
 

The Broadsmoore Group, LLC                                                                                            9,223,770(8)

560 Lexington Ave., 16 th Fl.

New York, NY 10022

 

PDA Associates LLC                                                                                                           7,770,000(9)

560 Lexington Ave., 16 th Fl.

New York, NY 10022


Officers, directors and 5 percent shareholders collectively                                        54,508,099(10)                                                                                                            59.74%


 

* Less than 1%

 

(1)      Unless otherwise indicated, each person or entity named in the table has sole voting power and investment power (or shares that power with that person's spouse) with respect to all shares of common stock listed as owned by that person or entity.

(2)      A total of 83,807,964 shares of the Company's common stock are considered to be outstanding pursuant to Rule 13d-3(d)(1) under the Securities Exchange Act of 1934.

(3)      Includes 32,821,641 shares of common stock held in his name and options to purchase 885,672 shares of common stock.

(4)      Includes 50,000 shares of common stock held in his name and options to purchase 885,672 shares of common stock,

(5)      Includes 1,050,000 shares of common stock held in his name and options to purchase 885,672 shares of common stock

(6)      Includes 50,000 shares of common stock held in his name and options to purchase 885,672 shares of common stock,

 

(7)      Includes 33,971,641 shares of common stock, options to purchase 3,542,688 shares of common stock and shares of Series A Convertible Preferred Stock convertible into 3,350,000 shares of common stock,

(8)      Includes 5,706,270 shares of common stock held in its name, warrants to purchase 167,500 shares of common stock and shares of Series A Convertible Preferred Stock convertible into 3,350,000 shares of common stock,

(9)      Includes 7,400,000 shares of common stock held in its name and warrants to purchase 370,000 shares of common stock,

(10)      Includes 47,077,911 shares of common stock, warrants to purchase 537,500 shares of common stock, options to purchase 3,542,688 shares of common stock and shares of Series A Convertible Preferred Stock convertible into 3,350,000 shares of common stock



http://ih.advfn.com/p.php?pid=nmona&article=5144097

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RGIN
Current Price
Volume:
Bid Ask Day's Range
SureTrader
RGIN News: Quarterly Report (10-q) 08/22/2016 05:18:07 PM
RGIN News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 08/15/2016 10:34:17 AM
RGIN News: Quarterly Report (10-q) 05/23/2016 05:23:57 PM
RGIN News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 05/16/2016 05:15:09 PM
PostSubject
#2389  Sticky Note RGIN FDA Grants Orphan-Drug Designation for Regenicin's NovaDerm HDOGTX 08/29/16 01:25:28 PM
#2463   Thats the moniker of all stocks in the Scotttrader80 09/15/16 10:30:32 AM
#2462   Great flag formation here @RGIN Liquid1974 09/10/16 05:08:46 PM
#2461   Great gain. Clark6290 09/09/16 01:36:36 PM
#2460   yes, i put the correct number up in gail 09/09/16 08:22:52 AM
#2459   Is the current updated # that has been applevision 09/08/16 10:52:42 PM
#2458   .02 to .06 applevision 09/08/16 10:48:26 PM
#2457   Going long? this may turn down again without applevision 09/08/16 10:39:56 PM
#2456   got some @ .055 today, gonna sit on Scotttrader80 09/08/16 03:44:32 PM
#2455   .10 ??? Perhaps decimal was off. Didn't hit Clark6290 09/02/16 12:20:37 PM
#2454   Lol. Massive reverse split we are not Clark6290 09/02/16 10:55:30 AM
#2453   REALLY!!!!!? when does the crystal ball say that Scotttrader80 09/01/16 11:33:09 AM
#2452   Slow and steady shurtha2000 08/31/16 09:43:16 AM
#2451   $1.20 high coming.... RGIN Liquid1974 08/30/16 07:39:14 PM
#2450   Higher highs and lows@ RGIN Liquid1974 08/30/16 05:04:27 PM
#2449   Nice close today... Liquid1974 08/30/16 05:02:10 PM
#2448   RGIN 330k Bid HDOGTX 08/30/16 12:42:18 PM
#2447   Look like .10 today shurtha2000 08/30/16 09:33:38 AM
#2446   Only 3 MM's under .15. Could be a retireat40 08/30/16 09:21:55 AM
#2445   Wow...you are truly clueless. retireat40 08/29/16 05:17:38 PM
#2444   Thats not what the 300K+ bid at .05 PennyStockPower 08/29/16 04:42:48 PM
#2443   ASCM may be well and truly screwed... retireat40 08/29/16 03:16:17 PM
#2442   CSTI at .05 on bid and .155 on retireat40 08/29/16 03:14:25 PM
#2441   wow, thats huge! ihub is....... gail 08/29/16 03:13:16 PM
#2440   Over $16,000 on the bid at .05. retireat40 08/29/16 03:11:39 PM
#2439   Should at least double from these levels. retireat40 08/29/16 03:11:38 PM
#2438   Huge bid at .05. retireat40 08/29/16 03:10:45 PM
#2437   welp, he said updates are coming, so, it gail 08/29/16 03:08:58 PM
#2436   gail, thanks. i don't own rgin anymore. i gonzilee 08/29/16 03:07:18 PM
#2435   no one is stuck. if someone chooses to gail 08/29/16 03:01:39 PM
#2434   well, be glad you sold. i sold the gonzilee 08/29/16 02:58:53 PM
#2433   He is clueless when it comes to this retireat40 08/29/16 02:58:19 PM
#2432   my pleasure. either way, it seems that they gail 08/29/16 02:57:48 PM
#2431   Thanks gail. mc6102 08/29/16 02:53:51 PM
#2430   last week, i got in last week. i gail 08/29/16 02:52:35 PM
#2429   you just posted that you don't even own gonzilee 08/29/16 02:51:31 PM
#2428   yeah... still waiting on that example of a mc6102 08/29/16 02:49:41 PM
#2427   the co is not pumping, he sounded like gail 08/29/16 02:49:18 PM
#2426   Your done? Awesome Diamond42 08/29/16 02:47:48 PM
#2425   well, sounds like he confirmed what i have gonzilee 08/29/16 02:43:01 PM
#2424   and if anyone is skeptical of the call, gail 08/29/16 02:36:09 PM
#2423   are you all noticing a delay when you gail 08/29/16 02:33:24 PM
#2422   dude, i have read all the fillings and VONGEBOB 08/29/16 02:32:59 PM
#2421   i just read him your post- i wanted gail 08/29/16 02:32:24 PM
#2420   big spreads - mms don't know which way tedpeele 08/29/16 02:28:13 PM
#2419   big spreads - mms don't know which way tedpeele 08/29/16 02:26:48 PM
#2418   he's been shorting for days. will continue, because gonzilee 08/29/16 02:26:31 PM
#2417   The broader market is just now hearing of Diamond42 08/29/16 02:24:37 PM
#2416   ASCM is shorting big time. we need to VONGEBOB 08/29/16 02:23:30 PM
#2415   "on fleek" - ROTFL. mc6102 08/29/16 02:21:59 PM
#2414   doesn't matter. company doesn't have anything new to gonzilee 08/29/16 02:21:30 PM
PostSubject